| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.076 | 0.2 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.2 |
| mRNA | Roscovitine | FIMM | pan-cancer | AAC | -0.23 | 0.2 |